Omeros Reports Q3 2026 Revenue Growth and Positive Operating Cash Flow
Omeros (OMER) reported strong commercial momentum in its third quarter of 2026, with gross product revenues reaching $41.8 million, a 30% increase from the previous quarter. Net product revenues rose 26% to $35.9 million, driven by expanded formulary access for YARTEMLEA and an increase in unique ordering accounts to 109. Despite a GAAP net loss of $57.4 million due to various factors, the company achieved non-GAAP adjusted net income of $4.7 million, marking a significant improvement over the second quarter. The company's balance sheet was strengthened by a $60.2 million debt repurchase and a $30.5 million convertible notes repurchase, which reduced outstanding principal by 43% and mitigated future dilution. While Omeros faces headwinds regarding a negative opinion from the CHMP in the European Union for narsoplimab and clinical delays for OMS527, it maintains positive operating cash flow for the second consecutive quarter and benefits from new Medicare NTAP reimbursement rates.

Tickers: $OMER